Categories
Change Password!
Reset Password!
The preoperative ferric carboxymaltose injection
reduces the requirement of RBC transfusion in patients undergoing total hip
arthroplasty.
A recent study published in the International Journal of clinical practice depicted that ferric carboxymaltose (FCM) injection administered preoperatively without any other supplementation could reduce the need of red blood cell (RBC) transfusion in individuals undergoing total hip arthroplasty (THA).
A total
of 1,032 patients undergoing unilateral THA from November 2014 to July 2018
were included in the retrospective study. They were divided into two groups.
The FCM group included 568 patients and the non-FCM group included 464
patients. The primary endpoint was to evaluate the inter-group difference in
the requirement of RBC transfusion.
The
propensity-score matching method led to 389 patients in each group. It was
observed that the amount and incidence of RBC transfusion in the FCM group were
remarkably lower compared with the non-FCM group, as illustrated in Table 1:
Thus, it
was concluded that the single preoperative FCM administration can be
recommended as an easy patient blood management strategy for reducing the RBC
transfusion in THA.
International Journal of Clinical Practice
Effect of single preoperative ferric carboxymaltose injection on perioperative transfusion in patients undergoing total hip arthroplasty: A retrospective analysis
Hyun-Jung Shin et al.
Comments (0)